Peptide boom has states scrambling to protect consumers, Post investigation finds

A Washington Post investigation reveals significant regulatory gaps in the US peptide market, with medspas selling unstudied compounds with minimal oversight compared to restaurants or salons. The FDA and state boards are struggling to keep pace as peptides proliferate in gray and black markets.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.